- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02393950
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers (FIMPAM)
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males
연구 개요
상세 설명
Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.
The study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일
- Parexel International GmbH
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent obtained.
- Participants must be able to speak, read and understand German.
- Good general health ascertained by detailed medical history and physical examinations.
- Males 18-45 years (inclusive).
- Body mass index (BMI) 18-30 kg/m2 inclusive
- Weight 55-95 kg (inclusive).
- Participants with female partners of child-bearing potential must adhere to a proper form of contraception from first study treatment administration until 3 months after the end-of-study visit.
Exclusion Criteria:
- A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator.
- Vulnerable subjects.
- Veins unsuitable for repeated venipuncture.
- Evidence of clinically relevant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects.
- Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease
- Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
- Definite or suspected personal history of hypersensitivity to drugs or excipients.
- Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication.
- A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) .
- Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study.
- History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.
- Propensity to get headache when refraining from caffeine-containing beverages.
- Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit.
- Abnormal 12-lead ECG finding of clinical relevance at the screening visit
- Heart rate (HR) < 50 bpm or > 90 bpm after 10 min in rest (supine) at the screening visit
- At the screening visit: systolic BP < 90 mmHg or > 140 mmHg, diastolic BP < 50 mmHg or > 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.
- Abnormal 24-h Holter of clinical relevance at the screening visit,
- Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.
- Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
- Participation in an investigational drug study within 2 months before entry into this study.
- An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor.
- Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
- Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Drug: ODM-106
Oral capsules dosage 2-800mg once daily for one day
|
Single oral escalating doses of ODM-106 will be administered.
Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
|
위약 비교기: Drug: Placebo
Oral capsules given once daily for one day
|
Single oral escalating doses of ODM-106 will be administered.
Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.
기간: From screening up to 16 weeks
|
Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.
|
From screening up to 16 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Peak Plasma Concentration (cMax) of ODM-106
기간: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
cMax of ODM-106 after single dosing of either Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106
기간: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
|
AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
|
Time to Peak Plasma Concentration (Tmax) of ODM-106
기간: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
|
tmax of ODM-106 after single oral dosing of Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
|
Elimination Half-life of ODM-106
기간: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Metabolite Screening in Plasma and Urine
기간: Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level
|
Metabolite screening in plasma and urine after single dosing
|
Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level
|
Effect of ODM-106 on Growth Hormone Levels
기간: Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
|
Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.
|
Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
|
Sedation Scores on a Visual Analogue Scale (VAS)
기간: Pre-dose and at 1, 6 and 10.5h post dose at each dose level
|
Assessment of sedation by subject
|
Pre-dose and at 1, 6 and 10.5h post dose at each dose level
|
Dexterity and Reaction Times
기간: Pre-dose and at 1 and 6h post dose at each dose level
|
Selected battery of psychomotor tests
|
Pre-dose and at 1 and 6h post dose at each dose level
|
Quantitative EEG
기간: Pre-dose and at 1, 6 and 10 h post dose at each dose level
|
Quantitative analysis of EEG
|
Pre-dose and at 1, 6 and 10 h post dose at each dose level
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Rainard Fuhr, MD, Parexel International GmbH, Berlin, Germany
- 연구 책임자: John Whiteside, Orion Corporation, Orion Pharma
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 3117001
- 2014-001317-33 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
건강한 자원 봉사 연구에 대한 임상 시험
-
Technical University of MunichBalgrist University Hospital; Deutsches Herzzentrum Muenchen알려지지 않은
ODM-106에 대한 임상 시험
-
Orion Corporation, Orion PharmaEndo Pharmaceuticals완전한
-
Orion Corporation, Orion Pharma완전한
-
Orion Corporation, Orion PharmaQuotient Clinical완전한
-
Orion Corporation, Orion Pharma완전한
-
Orion Corporation, Orion PharmaEndo Pharmaceuticals완전한
-
Bayer모병암대한민국, 미국, 라트비아, 중국, 오스트리아, 벨기에, 브라질, 콜롬비아, 체코, 에스토니아, 핀란드, 프랑스, 독일, 헝가리, 이스라엘, 이탈리아, 일본, 리투아니아, 네덜란드, 페루, 폴란드, 포르투갈, 루마니아, 러시아 연방, 슬로바키아, 스페인, 대만, 칠면조, 우크라이나, 영국, 캐나다, 세르비아, 남아프리카, 스웨덴, 불가리아, 멕시코, 아르헨티나, 호주, 벨라루스
-
Orion Corporation, Orion PharmaBayer완전한